Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight
Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches
Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panels
IRVING, Texas , March 25, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...
Caris reinforces the value of Whole Exome Sequencing and Whole Transcriptome Sequencing testing for cancer patients
Highlighting the critical role of Caris GPSai in improving cancer care
Caris AI Insights are proprietary and only available to Caris Life Sciences customers
IRVING, Texas , March 11, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...
Caris AI Insights are proprietary and only available to Caris Life Sciences customers
The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -0.43%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.30%. March E-mini...